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Abstract
Rift Valley fever (RVF), a vector-borne zoonotic disease caused by a phlebovirus (family Bunyaviridae), is considered to be one of the most
important viral zoonoses in Africa. It is also a potential bioterrorism agent. Transmitted by mosquitoes or by direct contact with viraemic
products, RVF affects both livestock and humans, causing abortion storms in pregnant ruminants and sudden death in newborns. The disease
provokes flu syndrome in most human cases, but also severe encephalitic or haemorrhagic forms and death. There is neither a treatment
nor a vaccine for humans. The disease, historically confined to the African continent, recently spread to the Arabian Peninsula and Indian
Ocean. Animal movements, legal or illegal, strongly contribute to viral spread, threatening the Mediterranean basin and Europe, where
competent vectors are present. Given the unpredictability of virus introduction and uncertainties about RVF epidemiology, there is an
urgent need to fill the scientific gaps by developing large regional research programmes, to build predictive models, and to implement early
warning systems and surveillance designs adapted to northern African and European countries.
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Rift Valley fever (RVF) is a vector-borne zoonotic disease
caused by a phlebovirus (family Bunyaviridae). RVF virus (RVFV)
is an enveloped RNA virus characterized by a genome
composed of three segments, designated L, M, and S, of
negative or ambisense polarity [1]. Like many bunyaviruses,
RVFV produces a non-structural protein encoded by the S
segment, the NSs protein, which acts as a virulence factor [2].
It is transmitted from ruminants to ruminants by mosquito
bites, mainly from the genera Aedes and Culex, but also from
the genera Anopheles and Mansonia, as recently suggested in
Madagascar and Kenya [3,4]. Direct transmission between
ruminants through contact with viraemic fluids, i.e. blood or
fetal liquid, is also strongly suspected. Humans are mostly
contaminated after contact with aborted fetal material, i.e.
placental membranes from infected ruminants, which contain
large numbers of virus particles and blood. Furthermore, RVFV
was observed or experimentally demonstrated to persist for
long periods in different biotic or abiotic settings: a laboratory
assistant was infected in a laboratory 4 months after the virus
was handled in this laboratory; the virus may be isolated from
carcase tissues such as spleen or liver between 36 and 72 h
after death; and infected sheep plasma retained RVFV
infectivity after 8 years of storage and shipment under a
variety of refrigeration conditions [5–8]. Consequently, veter-
inarians and laboratory, agricultural and slaughterhouse work-
ers may be at risk. If it exists, the viral load in raw milk is
assumed to be low. The presence of virus in nasal and
lachrymal secretions and the urine and faeces of infected
animals has not been demonstrated [1,9]. To date, no human-
to-human transmission of RVF has been documented.
The health and economic consequences of RVF outbreaks
are severe. Besides losses resulting from animal trade control,
RVFV infection causes abortion storms in pregnant ruminants
and acute deaths in newborns. However, the severity of clinical
signs depends on the species: sheep are more susceptible than
goats, which are themselves more susceptible than cattle and
camels. In adults, one may observe non-specific signs such as
vomiting, diarrhoea, respiratory disease, fever, lethargy, and
anorexia [10]. Although, in the majority of human cases, RVFV
causes a mild illness with fever, headache, myalgia, and liver
abnormalities, a minority of human cases of infection may lead
to either retinitis with permanent vision loss, encephalitis, or
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haemorrhagic forms that may lead to death [11]. During the
2000 Saudi Arabia outbreak, the major clinical characteristics
reported among 165 consecutive patients included a high
frequency (75%) of hepatocellular failure, acute renal failure for
42% of patients, and haemorrhagic manifestations for approx-
imately 19% of patients. A total of 56 patients died (33.9%)
[12]. There is no aetiological treatment, for either animals or
humans. Several vaccines are under development, but, to date,
there are no licensed and commercially available vaccines to
protect humans [13]. Regarding ruminants, the ‘Smithburn’
vaccine, a live attenuated vaccine, has been used for years in
Africa. It cheaply and efficiently protects sheep and cattle with
a single inoculation, but it may cause abortion or teratogenic
effects in fetuses, and may present a risk of reversion to
virulence: its use is thus reduced to endemic areas. A new,
promising live attenuated vaccine candidate—clone 13—was
obtained from a strain isolated from a mild human case in the
Central African Republic [14,15]. This vaccine was recently
registered and marketed in South Africa [16]. Owing to its
severity, RVFV is considered to be a major zoonotic threat to
the USA, and is number 3 on the list of the 17 most dangerous
animal threats, behind highly pathogenic avian influenza and
food and mouth disease [17].
Early detection and implementation of appropriate mea-
sures, which are essential to minimize the consequences of
outbreaks, require a deep understanding of transmission,
spread and persistence mechanisms. However, the epidemiol-
ogy of RVF is complex. The disease is enzootic in many African
countries and Madagascar, with outbreaks occurring every 5–
15 years. However, the factors triggering outbreaks and the
way in which the virus persists during inter-epizootic periods
remain mostly unknown. RVF has been reported in four
epidemiological systems:
1. ‘Dambo’ areas, in East Africa. Dambos are shallow depres-
sions that can be 1 km in length and several hundreds of
metres in width, and are often located in valleys near rivers.
In these areas, a correlation between heavy rainfall events
and RVF outbreak occurrence has been clearly demon-
strated. Viral transmission from one Aedes mcintoshi mos-
quito generation to another by ‘vertical transmission’, and
the survival of infected eggs in dry mud for several years,
could explain the maintenance of the virus in the field during
inter-epizootic periods [18,19].
2. Semi-arid areas of western Africa—Senegal and Mauritania
—characterized by temporary areas of water. In these
areas, a recent modelling study showed that outbreaks
could not be directly related to heavy rainfall events, but
mostly to abundant regular rainfall occurring throughout the
rainy season, which is favourable for successive high density
of the main vectors, i.e. Aedes vexans and Culex poicilipes [20].
The persistence of the virus may result from either the
above-mentioned vertical transmission in A. vexans mosqui-
toes or from the regular introduction of the virus by
nomadic herds [21].
3. Irrigated areas such as the Nile Delta or Senegal river basin,
where permanent water may favour Culex population
persistence, and thus RVFV transmission throughout the
year [22–24].
4. Temperate and mountainous areas, as recently demon-
strated in Madagascar, where transmission and spread result
from local vector-borne transmission associated with
specific cattle trade habits [25,26].
A role of wild ruminants, which is strongly suspected in
southern Africa, needs further investigation [27].
RVFV was historically confined to the African continent until
2000, when it was reported for the first time in the Arabian
Peninsula [28]; the geographical distribution of the virus has
recently increased. Global changes, including climatic changes,
may be involved. However, the natural history of RVF shows
that animal movements, legal or illegal, have strongly contrib-
uted to the spread of the virus [29–31]. Infected mosquitoes,
travelling in aircraft or cargoe, could also be incriminated [32].
Unprecedented increases in the international trade and
worldwide movements of humans, animals and animal products
are thus likely to alter the epidemiological patterns of RVF. In
fact, there is a large livestock trade between the sub-Saharan
countries where the virus is circulating and northern African
countries. The 2010 and 2012 Mauritanian outbreaks [33,34],
associated with the recent detection of serologically positive
camels in Morocco coming from the southern part of the
Saharan desert in a north-western direction [35], demon-
strated RVFV in northern Africa. Because of the illegal
importation of ruminants and the short geographical distance
between southern European coasts and northern Africa, the
exposure of the Mediterranean basin and Europe to RVFV has
increased. According to the European Food Safety Authority,
the virus could be introduced by either legally or illegally
imported infected animals, infected vectors, legally or illegally
imported contaminated animal products, fomites, or vaccines;
the first of these is the most plausible [36]. Even if this
probability is considered to be very low, because trading in
livestock from northern Africa and the Middle East to Europe is
forbidden, this introduction into an area of a dense and na€ıve
ruminant population may be devastating [37]. Conversely, and
because the virus can circulate with few or even no clinical
signs, it could remain undetected and settle in endemic foci in
areas where eco-climatic conditions are favourable. In fact, 50
mosquito species may transmit the virus, and some of them are
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present in Europe [36,37]. Among them, Culex pipiens, whose
European distribution is wide, is competent to transmit RVFV
[38]. The distribution of Aedes albopictus, which is another
potential vector of RVFV, has dramatically enlarged since its
first introduction [39,40]. Established homogeneous popula-
tions have been identified in Albania, Croatia, France, Greece,
Monaco, Montenegro, Italy, San Marino, Slovenia, and Spain
[41]. The changing European climate could facilitate this spread
to new areas [42], enlarging the distribution of areas suitable
for RVFV transmission.
RVF should be suspected when a sudden abortion storm or
sudden deaths of ruminants are associated or not with febrile
syndrome in humans. Depending on the epidemiological status
of the area, and the delay post-infection, diagnosis may be
performed either by detection of live virus, viral antigen or viral
nucleic acids within 1–10 days after the onset of the disease, or
by detection of acute-phase (IgM) or chronic (IgG) antibodies,
starting from 4 days post-infection [1]. Among recently vali-
dated tests, a sandwich ELISA for antigen detection (sAg-ELISA)
was recently reported [43], having, respectively, 67.7% and 70%
sensitivity for humans and sheep, and 97.9% and 100% specificity,
and real-time reverse transcriptase isothermal amplification
assays (RT-LAMP) have been developed and tested, allowing the
detection of a wide spectrumof isolates and in clinical specimens
in 30 min [44]. Inhibition ELISA tests for detecting IgG in all
species, capture ELISA for IgM for bovines, caprines and ovines
and sandwich ELISA for IgG for the same species are commer-
cially available. Finally, the virus neutralization test, which is
considered to be the reference standard, is highly accurate, with
no or few cross-reactions with other phleboviruses [45,46].
However, this methodology requires live virus, and thus can be
used only in biosafety level 3 laboratories [1].
Several control options are available, such as vaccines in
animals, larvicides in vector breeding sites and/or insecticide
spraying, animal trade control, and the provision of information
to exposed human populations. However, the disease is usually
well established in animal populations by the time when the first
human cases are observed [13]: in endemic areas, animal
vaccination is probably the best way to protect human health.
Regarding surveillance and virus-free areas, the use of a
dense sentinel herd network for surveillance would be cost-
prohibitive unless strictly focused on ecologically defined risky
areas. Syndromic surveillance relies on the early detection of
abnormal clusters of illness indicators rather than clinical signs,
and thus reduces the time-lag between the onset of the
outbreak and the diagnosis [47,48]. This methodology may be
a useful alternative in the case of RVF, which may provoke
non-specific signs, in either animals or humans: RVF human
cases were detected in 2009 in Mayotte thanks to the
surveillance for dengue-like syndromes [49].
In the Horn of Africa, RVF outbreaks can successfully be
predicted with lead times of 2–4 months, thanks to remotely
sensed data-driven models [50]. This early warning system is
based on accurate knowledge of the disease epidemiology. As
far as Europe is concerned, there is an urgent need to fill
scientific gaps, i.e. to experimentally evaluate European
potential vector competence and European ruminant breed
susceptibility, and to assess the existence of ruminant to
ruminant direct transmission. For implementation of a risk-
based surveillance network, European areas that are poten-
tially suitable for virus transmission need to be identified [51]:
given the current lack of knowledge, the multi-criteria decision
analysis method could be a valuable tool allowing the
integration of expert knowledge, the available literature and
data with trade—legal or illegal—information [52]. Further-
more, the epidemiological situation in northern African
countries, and the risk of introduction via either animal
movements or infected vector ‘travel’, should be assessed, as
well as the performance of both existing northern African and
European surveillance systems. In fact, a‘one-health’ regional
approach and a joint effort by human and animal health
authorities is needed to control RVF in endemic countries and
protect virus-free areas from introduction of the virus.
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